معرفی
Dr. Matthew Carter is a Senior Research Fellow at the University of Southampton, affiliated with the Faculty of Medicine and the Cancer Sciences department. He is part of the Antibody and Vaccine Group within the Institute of Developmental Sciences. Dr. Carter holds a First-Class Honours degree in Biochemistry (2008) and a PhD (2012) from the University of Southampton, both under the mentorship of Professor Mark Cragg. His research focuses on molecular cell biology and immunology, particularly the development of antibody-based therapies and small molecule inhibitors to enhance cancer immunotherapy. He is currently leading research projects targeting tumor hypoxia and antibody effector mechanisms in B-cell malignancies.
Education
- BSc (Hons) Biochemistry, University of Southampton, 2008
- PhD in Molecular Biology, University of Southampton, 2012
Research Interests
Dr. Carter’s work bridges molecular mechanisms and clinical applications, emphasizing:
- Antibody immunotherapy design and optimization
- Hypoxia’s role in tumor microenvironment dynamics
- B-cell biology, apoptosis regulation, and BH3-only proteins
- Synergistic drug combinations targeting lymphomas
- Development of preclinical models for therapeutic efficacy testing
Current Projects
He leads the Cancer Research UK-funded project Targeting Myeloid Cells For Improved Antibody Immunotherapy, collaborating with Professors Mark Cragg, Stephen Beers, and others. This work explores how myeloid cell recruitment can enhance antibody-based therapies.
Teaching
Dr. Carter co-leads the postgraduate MEDI6252 Cancer Immunology & Immunotherapy module and teaches MEDI6035 Cancer Immunology, covering topics like B-cell biology and tumor microenvironment interactions.
PhD Supervision
Current supervisees include Lili-May Ferson (iPhD Biomed), Thomas Wannell (iPhD Biomed), Garima Ahuja (PhD Cancer Sciences), and Minji Kim (PhD Cancer Sciences).
